FDA Introduces Strategy to Combat Food Smuggling
In early July 2011, FDA provided an update in which the agency said that it has made progress toward implementing the US Food Safety Modernization Act (FSMA), which was enacted in January 2011. In addition to clarifying expectations for new dietary ingredients through new draft guidance, the agency has issued an antismuggling strategy.
In early July 2011, FDA provided an update in which the agency said that it has made progress toward implementing the US Food Safety Modernization Act (FSMA), which was enacted in January 2011. In addition to clarifying expectations for new dietary ingredients through new draft guidance, the agency has issued an antismuggling strategy.
FDA worked with the US Department of Homeland Security to create the strategy, which aims to “identify and prevent smuggled foods from entering the United States and posing a threat to national security and consumer safety,” according to an agency press release. Although the strategy, like many portions of FSMA, focuses on food safety, many components and directives within the act also pertain to pharmaceuticals. Food-safety actions taken now may provide guidance for drug-safety issues in the future (see “FDA Gains Food Recall Authority, Drugs Could be Next”).
“This new system, overall, will better leverage the resources of federal agencies and it will make industry an important partner in safeguarding the health of US consumers,” said Deputy Commissioner for Foods Michael R. Taylor in the press release.
As part of the strategy, FDA will work with US Customs and Border Protection (CBP) to review historical data and better identify products, firms, and countries of origin to target potential food smuggling and smugglers. FDA and CBP also will share information on import shipments and conduct joint examinations to identify shipments that may contain smuggled food. FDA has been increasing its focus on drug imports at the borders as well with its Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting (PREDICT) computer system and its new spectral library system aimed at identifying excipients.
The agency also issued draft guidance regarding new dietary ingredients as part of FSMA implementation. The document aims to prevent consumers from being exposed to “unnecessary public-health risks from new ingredients with unknown safety profiles,” says the press release. Specifically, dietary-supplement manufacturers are required to notify FDA before adding a new dietary ingredient to their products, except when the ingredient has been part of the food supply and has not been chemically altered for use in supplements.
FDA has a website devoted to FSMA implementation and updates for more information.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
